In particular, MMP12 is significantly increased in AAAs while peroxisome proliferator-activated receptor γ agonist could reduce MMP12 levels, thus reducing the inflammatory and oxidative statuses of PVAT (77). This evidence concerns the gene MMP12 and achalasia-alacrima syndrome.